News Sort by Year All Years 2023 (3) 2022 (29) 2021 (17) 2020 (19) 2019 (12) 2018 (18) 2017 (19) 2016 (32) 2015 (43) 2014 (50) 2013 (32) 2012 (17) Search January 17, 2023 Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma January 17, 2023 Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference January 9, 2023 Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors December 1, 2022 Theriva Biologics to Participate in Upcoming Investor Conferences November 10, 2022 Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results November 10, 2022 Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results November 3, 2022 Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients November 3, 2022 Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results October 31, 2022 Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics October 24, 2022 Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
